Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ChAdOx1.HTI and MVA.HTI in Healthy Volunteers
NCT04563377Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Nov 2021
- Primary completion
- Aug 2022
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of ChAdOx1.HTI, MVA.HTI in human immunodeficiency virus infection (HIV), sponsored by University of Oxford. Started Nov 2021; status: completed.
02
Drugs
ChAdOx1.HTIMVA.HTI
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04563377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04563377.